Time magazine this month published an in-depth look at how collaboration is beginning to change the way cancer research is approached, citing numerous examples of the effectiveness of scientists working together to find a cure.
A new blood test technology may lead to major changes in treatment of Gastrointestinal Stromal Tumors. Keep reading for more information.
The LRG research team meets four times a year, with at least one in-person meeting per year. This year, the team held its in-person meeting at the LRG office in New Jersey March 22-24, 2013.
First report of a GIST patient responding to a BRAF inhibitor. Dr. Gerald Falchook and colleagues at MD Anderson Cancer Center provided the first report of a GIST patient responding to a BRAF inhibitor. The BRAF gene is frequently mutated in melanoma and BRAF inhibitors provide one of the most important therapies available for melanoma patients
Communication is a two-way street, but unfortunately that is not always the case when finding ways to research rare disease. Sharing of data by researchers does not happen as easily, or as often as you [...]
A recent study at Stanford University School of Medicine shows that an antibody slows GIST growth. The study shows that the antibody binds itself to the surface of a GIST Tumor and causes the growth of cancer cells to slow in the mice they tested.
Resecting GIST tumors may improve survival rates. Surgically removing residual gastrointestinal stromal tumors in patients who respond to imatinib therapy
The LRG Research Team recently held a teleconference that focused primarily on a study the team will collaborate on and intends to publish.
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
